Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $68.01 is 5.82% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 69.24||$ 89.54|
|Low:||$ 67.65||$ 64.27|
ETFs with GILD as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|8.46%||iShares Nasdaq Biotechnology Index Fund (IBB)||-5.15 (-4.77%)|
|7.05%||VanEck Vectors Biotech ETF (BBH)||-0.56 (-0.48%)|
|3.62%||iShares MSCI Global Impact ETF (SDG)||-1.21 (-2.14%)|
|2.51%||John Hancock Multifactor Healthcare ETF (JHMH)||+1.83 (5.76%)|
|1.82%||First Trust US Equity Dividend Select ETF (RNDV)||+0.20 (0.98%)|
|*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 days.|
Company Description (as filed with the SEC)
Gilead Sciences, Inc. (Gilead, we, our or us), incorporated in Delaware on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we strive to transform and simplify care for people with life-threatening illnesses around the world. We have operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead's primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases. We seek to add to our existing portfolio of products through our internal discovery and clinical development programs and through product acquisition and in-licensing strategies. ... More ...
Nasdaq Official Price
Nov. 19, 2018
Nov. 19, 2018